{
    "clinical_study": {
        "@rank": "8335", 
        "arm_group": [
            {
                "arm_group_label": "Allogeneic Mesenchymal Precursor Cells", 
                "arm_group_type": "Experimental", 
                "description": "Participants  randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of CEP-41750 into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results."
            }, 
            {
                "arm_group_label": "Control Treatment", 
                "arm_group_type": "Sham Comparator", 
                "description": "Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine whether transendocardial delivery of\n      allogeneic human bone marrow-derived MPCs (CEP-41750) is effective in the treatment of\n      chronic heart failure due to LV systolic dysfunction."
        }, 
        "brief_title": "The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure.", 
        "completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Heart Failure", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Ventricular Dysfunction, Left"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient is 18 to 80 years of age, inclusive; both men and women will be enrolled.\n\n          -  The patient has a diagnosis of chronic HF of ischemic or nonischemic etiology for at\n             least 6 months\n\n          -  The patient is on stable, optimally tolerated dosages of HF therapies including\n             beta-blockers (approved for country-specific usage), angiotensin-converting enzyme\n             (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and/or aldosterone\n             antagonists, without change in dose for at least 1 month before study intervention\n\n          -  The patient is on a stable, outpatient, oral diuretic dosing regimen in which the\n             patient remains clinically stable during screening.\n\n          -  Other Criteria apply, please contact the investigator\n\n        Exclusion Criteria:\n\n          -  The patient has NYHA Functional Class I or Functional Class IV symptoms.\n\n          -  Other Criteria apply, please contact the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1730", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032004", 
            "org_study_id": "C41750/3100", 
            "secondary_id": "2012-001818-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "Allogeneic Mesenchymal Precursor Cells", 
                "description": "CEP-41750 consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo,and cryopreserved", 
                "intervention_name": "Allogeneic Mesenchymal Precursor Cells (MPC)", 
                "intervention_type": "Biological", 
                "other_name": [
                    "CEP-41750", 
                    "MPC"
                ]
            }, 
            {
                "arm_group_label": "Control Treatment", 
                "description": "Scripted sham intracardiac mapping and cell delivery", 
                "intervention_name": "Sham Comparator", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Heart Failure", 
            "CHF", 
            "Left Ventricular Systolic Dysfunction", 
            "Ischemic Heart Failure", 
            "Nonischemic  Heart Failure", 
            "Stem Cells", 
            "Allogeneic Mesenchymal Precursor Cells"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "Teva Investigational Site 10757"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Teva Investigational Site 10756"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Teva Investigational Site 10754"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Teva Investigational Site 10759"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Teva Investigational Site 10760"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Teva Investigational Site 10765"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saginaw", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Teva Investigational Site 10766"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Teva Investigational Site 10762"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Teva Investigational Site 10761"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Teva Investigational Site 10758"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Teva Investigational Site 10767"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Teva Investigational Site 10755"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }, 
                    "name": "Teva Investigational Site 10763"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }, 
                    "name": "Teva Investigational Site 10764"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomized, Sham-procedure-controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP-41750) in Patients With Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology", 
        "overall_contact": {
            "last_name": "Teva US Medical Information", 
            "phone": "1-800-896-5855"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to first heart failure (HF)-related major adverse cardiac events (HF-MACE)", 
            "safety_issue": "No", 
            "time_frame": "5 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032004"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total hospital admissions for HF", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "measure": "Length of in-hospital stay for HF", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Cardiac survival", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "measure": "Overall survival (captures all cause deaths)", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Time to death from cardiovascular causes", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Change from baseline in 2-D echocardiography", 
                "safety_issue": "No", 
                "time_frame": "Baseline, months 3, 6, 12, 24, 36, 48, and 60"
            }, 
            {
                "description": "Assessed by change from baseline in distance covered", 
                "measure": "Change from baseline in exercise capacity during the 6-minute walk test (6MWT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, months 3, 6, 12, 24, 36, 48, and 60"
            }, 
            {
                "description": "Functional status as assessed by observation and examination by the investigator", 
                "measure": "Change in New York Heart Association (NYHA) functional class", 
                "safety_issue": "No", 
                "time_frame": "Baseline, months 3, 6, 12, 24, 36, 48, and 60"
            }, 
            {
                "description": "The MLHF questionnaire evaluates a total of 21 facets in questions using a scale ranging from 0 to 5, with 0 indicating 'No', 1 'Very Little' and 5 'Very Much' impact.", 
                "measure": "Change from baseline in the Minnesota Living With Heart Failure (MLHF) questionnaire score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and months  3, 6, 12, 24, 36, 48, and 60"
            }, 
            {
                "description": "A self-administered, subjective QoL questionnaire with 0 meaning Worst health and 100 meaning best health.", 
                "measure": "Change from Baseline in Quality of Life (QoL) EuroQoL 5-dimensional (EQ-5D) questionnaire score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, months 3, 6, 12, 24, 36, 48, and 60"
            }, 
            {
                "measure": "Summary of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "5 Years"
            }
        ], 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}